A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.

Phase 2

Eli Lilly and Company

Antibodies, Monoclonal